Premium
A weight loss formula, WL2, alters gene expressions in endocrine organs of DIO rats
Author(s) -
Zhang Lijuan,
Gao Ling,
Yao Yisang,
Zheng Taoye,
Zhou Yanjiao,
Zhu JiaShi
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.691.12
Subject(s) - endocrinology , medicine , calcitonin , thyroid , somatostatin receptor 2 , calcitonin receptor , endocrine system , adipose tissue , somatostatin , receptor , hormone , biology , somatostatin receptor , calcitonin gene related peptide , neuropeptide
We reported altered gene expressions in liver, muscle and adipose tissues, improving glucose, lipid and energy metabolisms, in response to WL2 therapy (FASEB J 21:A1352 & 21:A329, 2007). We further explored via microarray analysis the effects of WL2 (1.5g/kg for 10wks; n=20) in gene expressions in adrenal gland (AG), thyroid (T), hypothalamus (HT) and pituitary (P) of DIO rats. Along with significantly less gain of body weight, gene expressions were altered in many metabolic pathways in WL2 treated rats, as compared to controls (all p<0.05): (1) up‐regulated: a 3‐fold increase in gene expressions of calcitonin/calcitonin related polypeptide (Calca) in P, and a 68% increase in gene expressions of somatostatin receptor 2 (Sstr2) in AG; (2) down‐regulated: cannabinoid receptor family members (Cnr1, Cnr2) in AG, HT and P, all pro‐inflammation factors in endocrine organs, and thyroid hormone receptor in HT (−30%). Our data suggest that the weight loss by WL2 is a multi‐target outcome through alterations of multiple metabolic pathways, including regulating endocrine functions towards optimization of glucose, lipid, and energy metabolisms and anti‐inflammation.